Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib with Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
NCT02903069Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2016
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of marizomib in glioblastoma (GBM), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Aug 2016; status: completed.
02
Drugs
marizomib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02903069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903069.